Put Options

2 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.73 - $24.79 $197,414 - $292,522
11,800 New
11,800 $197,000
Q4 2023

Feb 14, 2024

BUY
$32.31 - $52.32 $13.5 Million - $21.9 Million
418,400 New
418,400 $15.2 Million

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $678M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.